175 related articles for article (PubMed ID: 31088197)
1. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
[No Abstract] [Full Text] [Related]
2. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
Thanarajasingam G; Maurer MJ; Farooq U; Johnston PB; Thompson CA; Bennani NN; Ansell SM; Porrata LF; Macon WR; Syrbu SI; Cerhan JR; Habermann TM; Link BK; Witzig TE; Nowakowski GS
Br J Haematol; 2018 Oct; 183(1):149-152. PubMed ID: 28961306
[No Abstract] [Full Text] [Related]
3. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
5. Central Nervous System Lymphoma.
Chukwueke UN; Nayak L
Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
[TBL] [Abstract][Full Text] [Related]
6. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Alcantara M; Houillier C; Blonski M; Rubio MT; Willems L; Rascalou AW; Le Garff-Tavernier M; Maloum K; Bravetti C; Souchet L; Roos-Weil D; Morel V; Uzunov M; Metz C; Dhib-Charfi M; Nguyen S; Shor N; Psimaras D; Weiss N; Jacque N; Solorzano S; Gauthier N; Le Cann M; Norol F; Soussain C; Choquet S
Blood; 2022 Feb; 139(5):792-796. PubMed ID: 34871363
[No Abstract] [Full Text] [Related]
7. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.
Riihijärvi S; Fiskvik I; Taskinen M; Vajavaara H; Tikkala M; Yri O; Karjalainen-Lindsberg ML; Delabie J; Smeland E; Holte H; Leppä S
Haematologica; 2015 Feb; 100(2):238-45. PubMed ID: 25381134
[TBL] [Abstract][Full Text] [Related]
8. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Roschewski M; Phelan JD; Wilson WH
Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
[No Abstract] [Full Text] [Related]
10. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Ayuk F; Gagelmann N; von Tresckow B; Wulf G; Rejeski K; Stelljes M; Penack O; Baldus CD; Kröger N; Bethge W; Dreger P
Blood Adv; 2023 Sep; 7(18):5316-5319. PubMed ID: 37450376
[No Abstract] [Full Text] [Related]
11. Successful Continuation of Clozapine in Conjunction With Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy: Case Report.
Kutzke JL; Leung JG; May HP; Nedved AN; DeFino CE; Bennani NN
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e194-e197. PubMed ID: 33272906
[No Abstract] [Full Text] [Related]
12. Local recurrence of primary central nervous system lymphoma due to tumor seeding.
Madkhali I; Bakshi N; Akhtar S; Maghfoor I
Ann Saudi Med; 2013; 33(3):310-1. PubMed ID: 23793439
[No Abstract] [Full Text] [Related]
13. Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
Gravenmier C; Shah B; Hussaini M; Zhang L
Leuk Lymphoma; 2024 May; 65(5):674-678. PubMed ID: 38240035
[No Abstract] [Full Text] [Related]
14. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
15. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.
Sethi TK; Reddy NM
Leuk Lymphoma; 2019 Jan; 60(1):6-18. PubMed ID: 29741421
[TBL] [Abstract][Full Text] [Related]
16. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model.
Tully S; Feng Z; Grindrod K; McFarlane T; Chan KKW; Wong WWL
JCO Clin Cancer Inform; 2019 Oct; 3():1-9. PubMed ID: 31644324
[TBL] [Abstract][Full Text] [Related]
17. Case 38: central nervous system lymphoma in a patient previously treated for Wegener's granulomatosis.
Lowry L; Cairns T; Thom M; Bain BJ
Leuk Lymphoma; 2008 Aug; 49(8):1610-1. PubMed ID: 18608863
[TBL] [Abstract][Full Text] [Related]
18. Are all chimeric antigen receptors created equal?
Park JH; Brentjens RJ
J Clin Oncol; 2015 Feb; 33(6):651-3. PubMed ID: 25605860
[No Abstract] [Full Text] [Related]
19. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
20. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
